Compares blood-thinning regimens in people with antiphospholipid syndrome and arterial clots
Studies blood-thinning treatments in adults with antiphospholipid syndrome after a recent arterial clot.
Plain-language title generated from the registry record
Registry title: Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
Key facts
- Where
- Hamilton, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with antiphospholipid syndrome who have had an arterial blood clot event. They must be taking one of four blood-thinning treatments. The follow-up is 2 years.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed antiphospholipid syndrome (Sydney criteria) with a first or repeated arterial clot event. This includes people with brain infarcts that cause no symptoms and are seen on imaging.
- Earlier treatment
- Must be treated with one of these: a vitamin K antagonist (VKA) with INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), a VKA alone with INR 2.0-3.0, a VKA with INR 3.0-4.0, or a dual antiplatelet regimen, if the treating doctor considers it appropriate.
Main reasons for not taking part
- Cannot be followed up because of distance or other reasons
- Documented poor compliance with treatment
- Bleeding risk that the doctor thinks makes combined blood-thinning treatment unsafe
- Pregnancy or planned pregnancy
- Vein clot event diagnosed after the last arterial event
Read by machine on 9 November 2026.
Where in Canada
- McMaster UniversityHamilton, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- McMaster University
- Trial code
- NCT05646394
- Record updated
- 9 December 2025
- Original description
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.Read full original descriptionShow less
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.
Inclusion: Patients of at least 18 years of age with confirmed antiphospholipid syndrome according to Sydney criteria and with first or recurrent arterial thrombotic manifestation, including those with asymptomatic brain infarcts on diagnostic imaging; Treatment with either A) a vitamin K antagonist (VKA) with therapeutic range, international normalized ratio (INR) 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0 or C) VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen, if considered appropriate by the treating physician; Signed informed consent obtained (in jurisdictions where required).
Exclusion: Bleeding risk that in the opinion of the treating physician makes combination antithrombotic therapy unsafe; Inability to follow the patient due to geographical or other reasons; Patients with documented poor compliance; Pregnancy or planned pregnancy; Venous thrombotic event diagnosed after the last arterial event.